Maximus, Inc. (NYSE:MMS - Free Report) - Zacks Research upped their Q1 2025 earnings per share estimates for shares of Maximus in a research note issued to investors on Wednesday, December 11th. Zacks Research analyst R. Department now expects that the health services provider will earn $1.39 per share for the quarter, up from their prior estimate of $1.38. The consensus estimate for Maximus' current full-year earnings is $5.89 per share. Zacks Research also issued estimates for Maximus' Q2 2025 earnings at $1.44 EPS, Q3 2025 earnings at $1.50 EPS, Q4 2025 earnings at $1.52 EPS, FY2025 earnings at $5.84 EPS, Q2 2026 earnings at $1.19 EPS, Q3 2026 earnings at $1.45 EPS, Q4 2026 earnings at $1.23 EPS, FY2026 earnings at $5.05 EPS and FY2027 earnings at $5.29 EPS.
Separately, StockNews.com lowered shares of Maximus from a "buy" rating to a "hold" rating in a report on Thursday, November 28th.
Read Our Latest Report on Maximus
Maximus Price Performance
MMS traded down $0.25 on Friday, reaching $70.46. 200,315 shares of the company's stock were exchanged, compared to its average volume of 430,193. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.49 and a quick ratio of 1.49. The stock's fifty day moving average price is $83.01 and its 200-day moving average price is $86.70. Maximus has a twelve month low of $69.74 and a twelve month high of $93.97. The stock has a market cap of $4.25 billion, a PE ratio of 14.13 and a beta of 0.73.
Institutional Investors Weigh In On Maximus
Several hedge funds and other institutional investors have recently made changes to their positions in MMS. V Square Quantitative Management LLC acquired a new position in shares of Maximus in the 3rd quarter valued at $25,000. Blue Trust Inc. lifted its stake in shares of Maximus by 201.5% in the second quarter. Blue Trust Inc. now owns 392 shares of the health services provider's stock valued at $33,000 after purchasing an additional 262 shares during the period. Archer Investment Corp boosted its stake in shares of Maximus by 8,788.9% during the 2nd quarter. Archer Investment Corp now owns 800 shares of the health services provider's stock worth $69,000 after acquiring an additional 791 shares in the last quarter. GAMMA Investing LLC grew its holdings in Maximus by 150.6% in the third quarter. GAMMA Investing LLC now owns 862 shares of the health services provider's stock valued at $80,000 after purchasing an additional 518 shares during the last quarter. Finally, Ariadne Wealth Management LP acquired a new stake in Maximus in the 2nd quarter valued at about $90,000. Institutional investors and hedge funds own 97.21% of the company's stock.
Insider Activity at Maximus
In other news, insider Michelle F. Link sold 2,208 shares of the business's stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $73.83, for a total transaction of $163,016.64. Following the completion of the transaction, the insider now directly owns 6,567 shares of the company's stock, valued at approximately $484,841.61. The trade was a 25.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.40% of the stock is currently owned by company insiders.
Maximus Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Saturday, November 30th. Investors of record on Friday, November 15th were paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 1.70%. The ex-dividend date of this dividend was Friday, November 15th. Maximus's payout ratio is 24.00%.
About Maximus
(
Get Free Report)
Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.
Recommended Stories
Before you consider Maximus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maximus wasn't on the list.
While Maximus currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
